{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335039","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2026-08-05T20:05:32+00:00","discovered_at":"2026-08-05T20:07:00.324022+00:00","generated_at":"2026-08-05T20:07:06.939643+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Revolution Medicines Q2 net loss $644M; FDA accepts daraxonrasib NDA for pancreatic cancer","bullets":["Net loss $644.4M vs $247.8M YoY; R&D $394.9M, G&A $110.2M; cash $3.9B.","FDA accepted daraxonrasib NDA for previously treated metastatic pancreatic cancer; Breakthrough Therapy Designation for NSCLC.","New combo data: zoldonrasib + SOC in 1L G12D NSCLC: 82% ORR, 100% DCR; elironrasib + SOC in 1L G12C NSCLC: 85% ORR, 97% DCR.","Completed $2.225B gross proceeds from stock and convertible note offerings; received $250M from Royalty Pharma.","Updated FY2026 GAAP operating expense guidance to $2.1-2.2B, including $270-290M stock-based comp."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335039","json":"https://secwatch.observer/filing/0001193125-26-335039.json","markdown":"https://secwatch.observer/filing/0001193125-26-335039.md","text":"https://secwatch.observer/filing/0001193125-26-335039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526335039/0001193125-26-335039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526335039/rvmd-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:07:06.939643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}